Lantheus Holdings, Inc. $LNTH Shares Bought by Sector Gamma AS

Sector Gamma AS grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 45.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 93,823 shares of the medical equipment provider’s stock after buying an additional 29,420 shares during the quarter. Lantheus comprises about 1.4% of Sector Gamma AS’s holdings, making the stock its 24th biggest position. Sector Gamma AS’s holdings in Lantheus were worth $6,244,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Quantbot Technologies LP acquired a new stake in Lantheus during the 3rd quarter valued at $1,847,000. Assetmark Inc. raised its stake in Lantheus by 20.1% during the 3rd quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after purchasing an additional 19,844 shares during the period. Vanguard Group Inc. raised its stake in Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after purchasing an additional 115,338 shares during the period. Heron Bay Capital Management acquired a new stake in Lantheus during the 3rd quarter valued at $861,000. Finally, Isthmus Partners LLC acquired a new stake in Lantheus during the 3rd quarter valued at $1,238,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citizens Jmp boosted their target price on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Finally, Truist Financial reissued a “buy” rating and set a $115.00 target price (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Trading Up 4.1%

NASDAQ LNTH opened at $104.32 on Friday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $104.50. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $6.79 billion, a PE ratio of 25.14 and a beta of -0.03. The firm’s fifty day simple moving average is $90.10 and its 200-day simple moving average is $76.44.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same period in the prior year, the business posted $1.53 earnings per share. Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.39 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.